Sep 20, 2021
|
STRIDE Data Show Translarna™ Delays Loss of Ambulation by More Than Five Years in Boys with Nonsense Mutation Duchenne Muscular Dystrophy
- Translarna was seen to slow disease progression compared to standard of care alone - - Data from long-term, real-world results from 241 patients in the STRIDE* patient registry - SOUTH PLAINFIELD, N.J. , Sept. 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc.
|
|
Sep 07, 2021
|
PTC Therapeutics Recognizes 2021 STRIVE Awards Recipients for Initiatives Supporting Duchenne Patient Community
- Patient Advocacy Organizations in Brazil and the U.K. Awarded Funding - SOUTH PLAINFIELD, N.J. , Sept. 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the three recipients who will receive funding through the company's STRIVE Awards program.
|
|
Aug 27, 2021
|
PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences
SOUTH PLAINFIELD, N.J. , Aug. 27, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Morgan Stanley Virtual 19 th Annual Global Healthcare Conference Friday, September 10 th at 11:00 a.m.
|
|
Aug 23, 2021
|
PTC Therapeutics Announces Waylivra™ Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome
- Approval Addresses Unmet Needs of Patients with No Other Treatment Options - SOUTH PLAINFIELD, N.J. , Aug. 23, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved
|
|
Aug 23, 2021
|
Targeting the Putamen with Gene Therapy Leads to Sustained Improvements in Motor and Non-Motor Functions in Children with AADC Deficiency
- Commentary Published in the European Molecular Biology Organization Journal - SOUTH PLAINFIELD, N.J. , Aug. 23, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of a manuscript, "Gene Therapy in the Putamen for Curing AADC Deficiency and Parkinson's
|
|
Aug 20, 2021
|
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , Aug. 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Aug. 17, 2021, it approved non-statutory stock options to purchase an aggregate of 51,670 shares of its common stock and 19,755 restricted stock units ("RSUs"), each representing
|
|
Jul 29, 2021
|
PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results
- Total quarterly net revenue of $117 million; 55% increase over second quarter 2020 - - Raises 2021 DMD franchise revenue guidance to $370-$390M from $355-$375M - - Progress across robust clinical pipeline with 3 ongoing registration-directed trials - SOUTH PLAINFIELD, N.J.
|
|
Jul 28, 2021
|
Significant Improvements in Survival and Developmental Milestones Demonstrated in Type 1 SMA Patients Treated with Evrysdi™
- Results from Part 2 of FIREFISH pivotal study published in the New England Journal of Medicine - SOUTH PLAINFIELD, N.J. , July 28, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from Part 2 of the FIREFISH pivotal study were published in the New England
|
|
Jul 15, 2021
|
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2021 Financial Results
SOUTH PLAINFIELD, N.J. , July 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2021 financial results and provide an update on the company's business and outlook on Thursday, July 29,
|
|
Jun 24, 2021
|
Results Add to Body of Evidence Confirming EMFLAZA®'s Benefit Over Prednisone
- Data presented at the 2021 Parent Project Muscular Dystrophy Annual Conference - SOUTH PLAINFIELD, N.J. , June 24, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented pooled placebo data from multiple studies in which the results confirmed the clinical benefit of EMFLAZA ®
|
|